A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, triple-dummy, clopidogrel-controlled study
of IV and oral PRT060128 compared to clopidogrel in patients undergoing non-urgent (including
elective) PCI. After diagnostic angiography, patients scheduled for non-urgent PCI will be
randomized to clopidogrel or to one of three dose levels of PRT060128.